SynthesisBMC cancer2025
Male-origin microchimerism and risk of cancer: a systematic review and meta‑analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany women carry male cells of presumed fetal origin-so-called male-origin microchimerism (MOM) in their circulation and tissues. The association between MOM and cancer risk remains unclear. We aim to evaluate the effect of MOM on cancer risk among postpartum women.
methodsA comprehensive literature search was conducted to identify relevant articles in databases of PubMed, EMBASE, and Web of Science. The data were extracted from eligible studies on the relationship between MOM and cancer risk. A random-effects model was applied to obtain the pooled relative risks (RRs) with 95% confidence intervals (95%CIs). Subgroup analysis, sensitivity analysis and publication bias and were also conducted.
resultsTwelve studies involving 3078 participants were enrolled in the pooled analysis. Data on the risk of breast, colon, ovarian, endometrial, thyroid, and brain cancer were collected for quantitative analysis. Pooled analysis showed a significantly reduced rate of cancer (pooled RR = 0.51, 95%CI 0.32-0.82) among MOM-positive women.
conclusionsIndividuals harboring MOM exhibits a significantly low risk of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.